Since antiestrogens are combined with CDK4/6 inhibitors in the clinic to treat advanced ER+ breast cancer, we sought to determine the effect of these drugs on cell proliferation in drug sensitive and resistant cells. Here, CDK4 is linked to breast carcinoma.